最少修改的人类凝血因子X,绕过直接的XA因子抑制剂
Mark Schreuder1, Georges Jourdi2, Dejvid Veizaj1
1Department of Internal Medicine, Division of Thrombosis and Hemostasis, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Journal of thrombosis and haemostasis : JTH
|May 10, 2024
概括
新的XA因子 (FXa) 变体可以克服直接的口服抗凝剂作用. 这些修改后的FXa蛋白显示出与抗凝血疗法相关的出血并发症的逆转剂的潜力.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
背景情况:
- 直接的口服因子 (F) Xa 抑制剂是静脉血栓栓塞和心房动的关键抗凝剂.
- 流血并发症是这些药物的重要关注点.
- 对于紧急情况,需要有效的逆转剂.
研究的目的:
- 评估工程化XA因子 (FXa) 变体在绕过直接口服FXa抑制剂的疗效.
- 为了研究这种绕道效应背后的机制.
主要方法:
- 人类FXa变种是通过用氨酸174 (F174) 替换氨酸,异氨酸或氨酸来创造的.
- 变种被表达,净化,并测试了它们在直接FXa抑制剂的存在下恢复血栓生成的能力.
主要成果:
- 通过直接的FXa抑制剂 (阿皮克萨班,里瓦罗克萨班,埃多克萨班),F174替代的FXa变体恢复了血中的血栓生成.
- 对抑制剂的敏感性降低是由于结合亲和力降低,由分子动力学模拟证实.
- 修改F174还减少了组织因子通路抑制剂的抑制,增强了前凝性活性.
结论:
- 工程FXa变种有效地抵消常见的直接FXa抑制剂.
- 这些FXa变种代表了危及生命的出血或紧急手术的有希望的救援策略.
- 有潜力减轻与直接口服FXa抑制剂治疗相关的风险.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
686
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
686
Extrinsic and Intrinsic Pathways of Hemostasis
7.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.3K
Coagulation
6.3K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.3K
Disorders of Hemostasis
862
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
862


